On December 31, 2024, the invention patent titled "A Biocompatible Photocurable 3D Printing Material and Its Preparation and Application" (Patent No.: ZL 2024 1 0820226.X), filed by Hangzhou Leyi New Material Technology Co., Ltd., was officially granted by the China National Intellectual Property Administration. This latest patent grant marks another breakthrough for LEYI®in the field of novel 3D printing materials and injects renewed vitality into the company’s sustainable development.
In recent years, 3D printing materials have gradually gained traction in the medical sector. Leveraging the advantages of rapid and precise intelligent manufacturing, 3D printing technology demonstrates expansive application potential for medical-grade materials. The patented invention provides a biocompatible 355nm-wavelength SLA (stereolithography) 3D printing material with enhanced mechanical properties and thermal resistance. This innovation addresses the limitations of conventional 355nm SLA materials, such as high toxicity and insufficient performance, making it suitable for large-scale rapid fabrication of medical devices, instruments, tissue engineering scaffolds, surgical guides, and other applications within the healthcare market.
